Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less

Executive Summary

A Senate Appropriations Committee-approved funding package would provide the Center for Drug Evaluation and Research with $5 million more than requested by the Obama administration
Advertisement

Related Content

Biosimilar, Generic and Rx User Fees Rely On Different Adjusters For Needed Appropriations
FDA's Medical Countermeasure Program Among Senate Funding Priorities
FDA To Offer Reviewers Rare Disease Training; Patient Groups Want Separate ODE
User Fee Discussions Include Funding Parts Of FDA Regulatory Science Plan
FDA Expects Sharp Drop In Fee-Paying Drug Applications This Year
Accelerated Approval: Mend, Don't End, Pazdur Tells ODAC After Avastin
Separate FDA Post-Market Drug Safety Office Outlined In Approps Bill Report
Sen. Brownback Wants FDA To Aggressively Coordinate Drug Development For Neglected/Rare Diseases
FDA Biosimilars Program Gets Seed Money In Administration's FY '11 Budget
Orphan, Tropical Diseases Need Better Drug Development Guidance - Senate

Topics

Advertisement
UsernamePublicRestriction

Register

PS052476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel